Related references
Note: Only part of the references are listed.The use of patient-reported outcomes (PROs) in cancer care: a realistic strategy
E. Minvielle et al.
ANNALS OF ONCOLOGY (2022)
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Sibylle Loibl et al.
BREAST (2022)
Quality-of-life methodology in hormone receptor-positive advanced breast cancer: Current tools and perspectives for the future
Fatima Cardoso et al.
CANCER TREATMENT REVIEWS (2022)
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Michael Gnant et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Masato Takahashi et al.
BREAST CANCER (2022)
Endocrine Therapy With or Without CDK4/6 Inhibitors in Women With Hormone-receptor Positive Breast Cancer: What do we Know About the Effects on Cognition?
Philippe R. Lee Meeuw Kjoe et al.
CLINICAL BREAST CANCER (2022)
Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy
Guillermo Villacampa et al.
CANCER RESEARCH (2022)
Quality of life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05)
Michelle Joy Naughton et al.
CANCER RESEARCH (2022)
Incidence of patient-reported fatigue developing in patients receiving palbociclib and endocrine therapy for advanced HR+HER2-breast cancer
Shadab A. Rahman et al.
CANCER RESEARCH (2022)
Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer
Gabriel N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Management ofAbemaciclib-AssociatedAdverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis ofMONARCH2 andMONARCH3
Hope S. Rugo et al.
ONCOLOGIST (2021)
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL
M. Martin et al.
ANNALS OF ONCOLOGY (2021)
A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application
David Richardson et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Original Research Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
Zsuzsanna Kahan et al.
EUROPEAN JOURNAL OF CANCER (2021)
Patients' quality of life and side effect perceptions in monarchE, a study of abemaciclib plus endocrine therapy in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer
S. Tolaney et al.
BREAST (2021)
Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib
Sarah Badaoui et al.
ONCOLOGIST (2021)
Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy
Kenichi Inoue et al.
BREAST CANCER (2021)
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
Matthew J. Page et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival
D. J. Slamon et al.
ANNALS OF ONCOLOGY (2021)
Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials
P. A. Fasching et al.
ANNALS OF ONCOLOGY (2021)
Quality of life from the Penelope-B study on high-risk HR+/HER2-early breast cancer patients treated with endocrine therapy with or without palbociclib
J. A. Garcia-Saenz et al.
ANNALS OF ONCOLOGY (2021)
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded population
Michelino De Laurentiis et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2-advanced breast cancer (ABC).
Debu Tripathy et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A mixed-methods study of cyclin-dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers
Laura B. Oswald et al.
CANCER MEDICINE (2021)
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy
Peter A. Kaufman et al.
ONCOLOGIST (2020)
Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
Laura M Spring et al.
LANCET (2020)
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial
Aleix Prat et al.
LANCET ONCOLOGY (2020)
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial
Sara M. Tolaney et al.
LANCET ONCOLOGY (2020)
Palbociclib-letrozole as first-line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
Masato Takahashi et al.
CANCER MEDICINE (2020)
Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2,-3, and-7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptore-positive, HER2-negative (HR+/HER2L) advanced breast cancer (ABC)
P. A. Fasching et al.
ANNALS OF ONCOLOGY (2020)
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
F. Cardoso et al.
ANNALS OF ONCOLOGY (2020)
Health-RelatedQuality of Life inMONARCH3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy inHR+,HER2-Advanced Breast Cancer
Matthew P. Goetz et al.
ONCOLOGIST (2020)
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
Peter A. Fasching et al.
BREAST (2020)
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Harold J. Burstein
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
Soohyeon Lee et al.
CANCERS (2020)
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
Nadia Harbeck et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
Patient-reported outcomes, including work productivity, from the MONALEESA-7 trial of ribociclib plus endocrine therapy in patients with HR+/HER2-advanced breast cancer
Nadia Harbeck et al.
CANCER RESEARCH (2020)
Quality of life in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer treated with palbociclib in real-world practice settings
Gabrielle Rocque et al.
CANCER RESEARCH (2020)
Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study
Denise A. Yardley et al.
CLINICAL BREAST CANCER (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
308PDUpdated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial
Y-S Lu et al.
ANNALS OF ONCOLOGY (2019)
Current state of quality of life and patient-reported outcomes research
Andrew Bottomley et al.
EUROPEAN JOURNAL OF CANCER (2019)
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
H. S. Rugo et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Yeon Hee Park et al.
LANCET ONCOLOGY (2019)
Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
H. S. Rugo et al.
ANNALS OF ONCOLOGY (2018)
First-line ribociclib plus letrozole in postmenopausal women with HR+, HER2-advanced breast cancer: Tumor response and pain reduction in the phase 3 MONALEESA-2 trial
Wolfgang Janni et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Health-related quality of life of postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treated with ribociclib plus letrozole: results from MONALEESA-2
Sunil Verma et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Targeted Therapy for Premenopausal Women with HR+, HER2- Advanced Breast Cancer: Focus on Special Considerations and Latest Advances
Aditya Bardia et al.
CLINICAL CANCER RESEARCH (2018)
Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Vered Stearns et al.
CLINICAL BREAST CANCER (2018)
Palbociclib plus endocrine therapy in older women with HR+/HER2-advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies
Hope S. Rugo et al.
EUROPEAN JOURNAL OF CANCER (2018)
Maintenance of health-related quality of life in elderly patients treated with ribociclib plus letrozole in MONALEESA-2
Howard A. Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
N. C. Turner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper
Nicolo Matteo Luca Battisti et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew P. Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Patient-reported outcomes in cancer survivorship
Brittaney-Belle E. Gordon et al.
ACTA ONCOLOGICA (2017)
Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial
N. Harbeck et al.
ANNALS OF ONCOLOGY (2016)
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment
T. Bell et al.
CURRENT MEDICAL RESEARCH AND OPINION (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Health, Health-Related Quality of Life, and Quality of Life: What is the Difference?
Milad Karimi et al.
PHARMACOECONOMICS (2016)
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
N. I. Cherny et al.
ANNALS OF ONCOLOGY (2015)
Inclusion of patient-reported outcome measures in registered clinical trials: Evidence from ClinicalTrials.gov (2007-2013)
E. Vodicka et al.
CONTEMPORARY CLINICAL TRIALS (2015)
Share Paper
